Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CONCORD DRUGS vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CONCORD DRUGS   MYLAN
EQUITY SHARE DATA
    CONCORD DRUGS
Mar-23
MYLAN
Dec-18
CONCORD DRUGS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs423,969-   
Low Rs202,185-   
Sales per share (Unadj.) Rs55.91,826.5-  
Earnings per share (Unadj.) Rs1.149.6-  
Cash flow per share (Unadj.) Rs2.8391.6-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs33.41,975.9-  
Shares outstanding (eoy) m9.32514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.51.7 32.5%   
Avg P/E ratio x28.962.0 46.6%  
P/CF ratio (eoy) x10.97.9 138.8%  
Price / Book Value ratio x0.91.6 58.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m2851,583,163 0.0%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m380-   
Avg. sales/employee Rs Th026,849.2-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0729.1-  
INCOME DATA
Net Sales Rs m521939,722 0.1%  
Other income Rs m00-   
Total revenues Rs m521939,722 0.1%   
Gross profit Rs m46243,165 0.0%  
Depreciation Rs m16175,953 0.0%   
Interest Rs m1745,197 0.0%   
Profit before tax Rs m1222,015 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3-3,502 -0.1%   
Profit after tax Rs m1025,517 0.0%  
Gross profit margin %8.825.9 33.9%  
Effective tax rate %21.1-15.9 -132.6%   
Net profit margin %1.92.7 69.7%  
BALANCE SHEET DATA
Current assets Rs m435524,740 0.1%   
Current liabilities Rs m216382,593 0.1%   
Net working cap to sales %41.915.1 277.2%  
Current ratio x2.01.4 146.6%  
Inventory Days Days784 7.8%  
Debtors Days Days1,10893 1,187.4%  
Net fixed assets Rs m148182,291 0.1%   
Share capital Rs m93500 18.6%   
"Free" reserves Rs m2180-   
Net worth Rs m3111,016,607 0.0%   
Long term debt Rs m191,097,246 0.0%   
Total assets Rs m5822,726,936 0.0%  
Interest coverage x1.71.5 116.5%   
Debt to equity ratio x0.11.1 5.7%  
Sales to assets ratio x0.90.3 259.5%   
Return on assets %4.62.6 178.3%  
Return on equity %3.22.5 126.1%  
Return on capital %8.93.2 281.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m17195,274 0.0%  
From Investments Rs m-23-100,935 0.0%  
From Financial Activity Rs m6-90,970 -0.0%  
Net Cashflow Rs m01,618 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.39 Rs / USD

Compare CONCORD DRUGS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CONCORD DRUGS With: SURYA PHARMA  PHARMAIDS PH  KWALITY PHARMA  SHAMROCK IND  VINEET LABORATORIES  



Today's Market

Sensex Today Rallies 941 Points | Bank Nifty Hits Record High | 5 Reasons Why Indian Share Market is Rising Sensex Today Rallies 941 Points | Bank Nifty Hits Record High | 5 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.